Accelerated cancer drug approvals deliver limited survival gains at high cost – BioNews Central Early access to new cancer drugs through the FDA’s accelerated approval pathway provided mixed patient benefits and cost Medicare billions, with fewer than half of the drugs subsequently shown to extend survival. ...

Early access to new #CancerDrugs through the #FDA ’s accelerated approval pathway provided mixed #PatientBenefits and cost #Medicare billions, with fewer than half of the drugs subsequently shown to extend survival.
#CancerTherapies #DrugCost #HealthcareCosts

10/11 The strike's resolution reduces wait times for needed health tests, benefiting patients. Yet underlying questions persist about profit-driven healthcare delivery versus public service priorities in essential diagnostic services.
#PatientBenefits #HealthcareDelivery